All In Biotech

NDA 022192 · Vanda Pharms INC

Fanapt

Iloperidone · Oral · Atypical Antipsychotic

Novel

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 6, 2009

Approved uses

3

Original approval plus efficacy supplements

Registered trials

27

5 Phase 3, 3 recruiting

FAERS reports

1,476

722 serious, 60 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect May 6, 2026.

FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )

Mechanism: The mechanism of action of iloperidone in schizophrenia and bipolar I disorder is unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • FANAPT · ILOPERIDONE 12MG · TABLET, ORAL · Prescription · TE AB
  • FANAPT · ILOPERIDONE 8MG · TABLET, ORAL · Prescription · TE AB
  • FANAPT · ILOPERIDONE 4MG · TABLET, ORAL · Prescription · TE AB
  • FANAPT · ILOPERIDONE 1MG · TABLET, ORAL · Prescription · TE AB
  • FANAPT · ILOPERIDONE 10MG · TABLET, ORAL · Prescription · TE AB
  • FANAPT · ILOPERIDONE 6MG · TABLET, ORAL · Prescription · TE AB
  • FANAPT · ILOPERIDONE 2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Iloperidone" as an intervention, any sponsor and status, largest first.

All 27 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective108
  • dizziness107
  • insomnia83
  • weight increased83
  • anxiety70
  • fatigue68
  • nausea54
  • dyskinesia51
  • suicidal ideation49
  • dyspnoea48
  • off label use48
  • somnolence48

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
201075
2011134
2012393
201376
201484
201564
201660
201782
201876
201987
202046
202149
202234
202327
202428
202573
202687

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fanapt (Iloperidone)

2024 spending

$87.3M

Beneficiaries

4,229

41,979 claims

Per beneficiary

$20,648

$42.46 per unit

View as table
YearSpending
2020$80,887,041
2021$90,157,616
2022$94,005,689
2023$92,779,041
2024$87,322,405

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Vanda Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.